Wellness & Lifestyle

Scailyte is a TechBio company dedicated to advancing precision medicine through the application of AI and multi-omics data. Their core offering, ScaiVision™, utilizes proprietary Supervised Representation Learning and Generative AI to analyze single-cell and spatial omics data. This approach allows for the unbiased identification of complex molecular patterns linked to clinical outcomes, enabling the discovery of novel biological signals. Scailyte is building a deep Autoimmune Foundation Model, anchored by single-cell and spatial data matched with longitudinal clinical outcomes, with a flagship program focused on Inflammatory Bowel Disease (IBD). They partner with pharmaceutical companies for asset de-risking, trial stratification, target discovery, and precision diagnostics.

ThinkBio.Ai offers AI-powered software solutions for healthcare and life sciences, focusing on computable biology to bridge the gap between fragmented data and actionable insights. Their platforms integrate biological knowledge, AI models, and clinical intelligence to make biology transparent and actionable. They help organizations overcome data silos, reduce translational risk, and accelerate precision medicine across biopharma research and clinical care. ThinkBio.Ai provides solutions for biopharma, including target discovery, clinical trial optimization, and drug repurposing, as well as healthcare and precision medicine, such as patient stratification and AI-based report generation. The company emphasizes secure, compliant, and certified solutions, holding certifications like ISO 27001 and HIPAA.

Koliber Biosciences specializes in applying data science, machine learning, and artificial intelligence to biological research, offering solutions from traditional statistical analysis to advanced AI systems. Their core offerings include custom machine learning model development for biological data, with expertise in feature-based ML, deep learning, data augmentation, transfer learning, and explainable AI. They have developed an AI-assisted platform for peptide drug discovery, which analyzes complex datasets to pinpoint performance drivers, predict in vivo results, identify active sites, and select improved variants. Additionally, Koliber Biosciences provides statistics training and consulting, focusing on practical application for biological researchers, and is actively developing genome engineering technologies for microbiome and probiotic strains, leveraging machine learning for novel genetic control elements.

Trials.ai by ZS is an advanced AI-powered platform designed to revolutionize clinical study design for modern research teams. It leverages agentic AI technology to digitize, automate, and infuse intelligence into every stage of trial creation. The platform includes applications like Smart Designer for building complete clinical studies with intelligent automation and AI-powered recommendations, and Library Manager for accessing reusable knowledge. Data products such as Clinical Studies Ontology and Banzai Pipeline facilitate rapid document digitization and data ingestion via NLP, NER, and LLMs. Trials.ai also features Franklin, an AI Optimization Advisor, which provides expert guidance across clinical science, biostatistics, regulatory strategy, and medical writing to optimize study design in real time, focusing on improving design decisions before they become locked into downstream documents.

Biofy is a Brazilian HealthTech company that leverages artificial intelligence and cutting-edge genomic analysis to revolutionize microbiology diagnostics. Their core solution, Abby Recommender, combines 4th generation DNA sequencing with AI trained on over 75 TB of genomic data to identify bacterial infections, predict antibiotic resistance, and recommend the most effective treatment within hours. This rapid diagnosis, typically within 4 hours, significantly reduces the time patients wait for effective treatment, thereby minimizing complications, prolonged hospital stays, and mortality risks. Biofy aims to optimize hospital resources, reduce costs, and effectively contribute to the global fight against antimicrobial resistance by providing reliable and personalized clinical recommendations.

Exaris Solutions offers Vertical Search Health, an AI-powered platform designed to revolutionize HCP (Healthcare Professional) targeting in the pharmaceutical industry. The tool leverages AI to scan millions of healthcare data points, identifying the most relevant HCPs based on specialty, prescribing behavior, geographic location, and engagement patterns. It eliminates manual research, providing instant recommendations for high-value targets. Vertical Search Health also enables smart segmentation and insights, categorizing HCPs into precision-based segments and predicting engagement likelihood using AI-driven scoring models. Furthermore, it automates messaging personalization for outreach, suggesting optimal communication channels and ensuring compliance with industry standards. The platform continuously learns and optimizes strategies based on real-time performance data, tracking key metrics and providing actionable recommendations to refine outreach efforts.

AIDPATH, an EU project, focuses on AI-powered, decentralized production of Advanced Therapies in the Hospital, specifically CAR-T cells for cancer treatment. The system integrates patient-related data and biomarkers using artificial intelligence to tailor therapies. CAR-T cells are produced close to the patient, directly in the hospital, enabling faster delivery of personalized treatments. The automated production involves heterogeneous machines connected via standardized interfaces, controlled by service-oriented software. This software is enhanced by an AI-based digital cell twin for initial process parameters and an AI process controller for real-time adjustments, ensuring efficient and customized therapeutic outcomes.

Swoop, formerly known as conversationHEALTH, is an AI-driven platform specializing in omnichannel healthcare marketing. It enables pharmaceutical brands to engage both direct-to-consumer (DTC) and healthcare professional (HCP) audiences with precision and at scale, while ensuring 100% privacy compliance. The platform offers solutions for predictive audiences, TV audiences, and community engagement, leveraging real-world health data to identify and activate target segments. Swoop's privacy-by-design approach includes HIPAA-compliant de-identification of health data and a zero-knowledge methodology, making it a necessity for marketers navigating tightening privacy regulations. It helps marketers understand, find, activate, and engage unified audiences across all channels to improve patient outcomes.

Dot Compliance offers an AI-powered electronic Quality Management System (eQMS) specifically designed for the life sciences industry. Built on the Salesforce platform, it provides a comprehensive suite of solutions for clinical, regulatory, and quality management. Key processes covered include document management, change management, audit management, training management, CAPA management, and risk management. The platform features "Dottie," an AI assistant trained on quality management workflows, to help strengthen processes, save time, and reduce costs. Dot Compliance is pre-built and pre-validated, incorporating industry best practices for rapid deployment and lower total cost of ownership, making it ideal for pharmaceutical, biotechnology, and medical device companies.

MDI Health is an AI-driven platform designed to revolutionize medication management for healthcare payers and providers. It serves as an AI co-pilot, offering personalized analysis and recommendations to optimize medication regimes, reduce costs, and improve clinical outcomes. The platform helps organizations boost STARs and medication-related quality measures by utilizing real-time analytics to prioritize urgent quality gaps and track outcomes. It also identifies patients at risk of non-adherence and delivers interventions to improve quality measures while reducing Rx and medical spend. MDI Health's technology combines cutting-edge medical and pharmacological AI with clinical expertise to analyze patient cases holistically and deliver personalized clinical recommendations at scale, leading to significant savings and efficiency improvements.

Numerion Labs offers an AI superplatform designed to revolutionize drug discovery by exploring vast chemical spaces to identify novel, drug-like molecules. Leveraging machine learning, the platform aims to uncover previously unseen potential in molecular structures, accelerating the identification and development of new drugs. The company focuses on delivering first- and best-in-class potential in immune and inflammatory diseases through programs born from its superplatform. Numerion Labs is backed by a world-class team of scientists and engineers dedicated to redefining small-molecule drug discovery, making it a valuable tool for pharmaceutical companies and research institutions.

MSCA SE CardioSCOPE is an EU-funded research project dedicated to advancing the understanding and treatment of cardiovascular diseases (CVDs), particularly acute coronary syndrome (ACS). The project brings together experts from academia and companies across Europe to exchange and expand expertise in interdisciplinary approaches. It employs a comprehensive multiomic strategy, integrating various biological data types, alongside artificial intelligence and machine learning techniques, to develop personalized assessment and predictive models for ACS and major adverse cardiovascular events (MACE). The initiative focuses on enhancing Europe's research and innovation capacity in CVDs, moving beyond traditional risk factors to more patient-oriented and personalized strategies.

HealthMatch is a digital health platform designed to accelerate patient recruitment for clinical trials by leveraging artificial intelligence. The platform efficiently matches patients with suitable clinical trials based on their unique medical profiles, ensuring real-time and accurate connections. By streamlining the patient recruitment process, HealthMatch aims to advance life-saving cures faster through the power of machine learning and AI. This tool is particularly valuable for patients seeking new treatment options and for researchers looking to quickly enroll qualified participants for their studies, ultimately contributing to the faster development of new therapies.

BEYOND GENOMiX is a Swiss deeptech startup specializing in the analysis of aging hallmarks to advance the diagnosis of age-associated diseases and facilitate drug discovery. The platform utilizes a comprehensive genomics pipeline to explore molecular patterns linked to telomere and senescence pathways. With world-leading high-throughput technology for telomere analysis and AI-powered senescence biomarker analysis, BEYOND GENOMiX identifies new patterns in age-related diseases. Their proprietary machine learning platform integrates multi-omics data from decades of clinical studies, providing actionable insights for therapeutics and diagnostics by performing end-to-end analysis of telomeres, senescence, and key genetic variants.

The Medical Artificial Intelligence Laboratory (MAI Lab) is a glocal research hub comprising Biomedical Scientists and Clinicians dedicated to fostering a sustainable AI ecosystem in medical diagnostics. Their primary goal is to accelerate the translation of high-value AI innovations from research models into clinical practice throughout Africa. MAI Lab engages in various activities including research projects, publications, training programs, and events like the Health AI For All Network Conference (HAICon) 2026. They also offer internship and Student Industrial Work Experience Scheme (SIWES) programs for Nigerian students passionate about applying technology to healthcare, aiming to build a network of healthcare innovators.

Avenio AI is a Pharma-focused AI platform designed to accelerate clinical trials, regulatory compliance, and research for BioPharma and CROs. It leverages company-trained LLMs and agentic AI assistants to optimize protocol development. The platform features an intelligent Protocol Hub for end-to-end clinical protocol authoring, real-time collaboration with granular access control, and built-in risk detection. It helps clinical teams surface inconsistencies early, reduce rework, and maintain accurate references with integrated citation tools. Built on over 12,000 protocols and 70 billion clinical data points, Avenio AI aims to enhance efficiency without compromising scientific rigor, ensuring enterprise-grade security and compliance.

Phare Bio is a social venture dedicated to combating the global antimicrobial resistance (AMR) crisis by leveraging novel AI and Deep Learning. The company is developing AIBiotics, a generative AI platform designed to discover and develop new classes of antibiotics, specifically targeting urgent threats like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Phare Bio employs a unique business model, using donor funding for preclinical development to de-risk candidates and then partnering with pharmaceutical companies for clinical trials. This approach aims to streamline the drug discovery process, accelerating the identification and development of AI-optimized antibiotic candidates to address the critical need for new treatments.

Proxima, formerly known as VantAI, is an advanced AI-powered platform dedicated to revolutionizing drug discovery by decoding and designing the interfaces of life. The platform's mission is to make protein interactions programmable, focusing on inducers, modulators, and blockers. It features an integrated discovery platform built with three complementary, phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. Proxima actively works with industry leaders and has recently announced significant collaborations and funding rounds, including an $80 million seed round. The company also hosts a lecture series on Generative AI in Drug Discovery, showcasing its commitment to advancing scientific understanding and application in the field.

Clinakos Inc. offers a comprehensive platform that combines curated patient data with advanced AI tools, specifically designed for rare disease and oncology analytics. With over 13 years of expertise, Clinakos provides Medically Smart AI™ agents for intelligent answers, Clarion™ for self-service data exploration, Acceleron™ for AI-powered diagnosis verification and patient identification, and Confirmis™ for integrated patient data. The platform links fragmented primary sources like EMR, claims, and labs with patient-generated information to create comprehensive, de-identified patient profiles. Clinakos serves life sciences and biotech companies, healthcare providers, and consulting firms, enabling them to build their own patient data networks and registries for strategic initiatives from discovery through commercialization.

Aizon provides intelligent GxP manufacturing solutions through its AI-powered software as a service platform. The tool helps pharmaceutical companies improve yield, reduce deviations, and ensure product quality by offering real-time, practical AI applications. Key products include Aizon Execute for revolutionizing batch processing, Aizon Unify for AI-powered contextualized data and analytics, Aizon Predict for yield optimization and deviation reduction, and Aizon Agentic Studio for building dashboards and dynamic applications with natural language. Aizon is built by pharma manufacturing professionals, empowering users to solve complex problems and optimize manufacturing activities with predictive solutions. Consulting services are available to adapt solutions to specific needs, aiming for first results in weeks.

TuringDB is a high-performance, in-memory graph database engineered for real-time, multi-hop analytics and deep reasoning at scale. It offers lightning-fast graph analytics for deeply connected data, outperforming traditional databases by orders of magnitude with sub-millisecond query execution. The database supports over 500 million nodes for real-world scale and ensures low-latency queries for a smooth user experience. TuringDB features zero-lock concurrency to prevent read and write competition, full snapshot isolation for reproducibility and auditability, and Git-like versioning for auditable graphs and time-travel analytics. It allows rich metadata storage on nodes and edges, making it ideal for digital twins, LLMs, and agentic AI systems that require extensive context. Compatible with Cypher, users can query TuringDB graphs at scale without learning a new language.

Horus ML provides an integral platform offering diverse AI-based solutions specifically tailored for the healthcare sector, with a focus on clinical-assistance. The company has developed specialized tools that enhance clinical decision-making through intelligent assistance in three key areas: diagnostic imaging, precision medicine, and remote monitoring. Their solutions include Clover for predicting hidden cancer post-TEV, Horus Cardio Monitor for remote monitoring of heart failure patients, Deep Horus for pneumological diagnosis and prognosis, and Horus Oncologist for predicting therapeutic response in pancreatic cancer. Horus ML differentiates itself through its application of sophisticated Machine Learning algorithms, specialization in healthcare innovation with clinical profiles on its team, easy integration via a centralized platform, and the provision of validated, certified solutions alongside custom developments. The project is driven by a strong vocational component, aiming to improve healthcare and generate a positive societal impact.

OccamzRazor is at the forefront of innovative drug discovery, leveraging advanced digital science and machine learning methods to accelerate the understanding and treatment of brain aging. The platform's primary focus is on Parkinson's disease, aiming to map out the complexities of the condition to develop effective cures. By applying sophisticated AI techniques, OccamzRazor seeks to enhance the efficiency and success rates of pharmaceutical research and development, moving beyond traditional approaches to unlock new therapeutic possibilities. This tool is designed for researchers and scientists in the pharmaceutical and biotech sectors who are dedicated to tackling neurodegenerative diseases.

PharmaBug serves as a comprehensive global pharmaceutical directory, enhanced with advanced AI-powered discovery tools. The platform is specifically designed to accelerate research and development within the pharmaceutical industry. It offers a suite of tools aimed at streamlining critical processes such as target identification, lead optimization, and virtual screening. By leveraging artificial intelligence, PharmaBug facilitates faster and more efficient R&D cycles, helping researchers and companies bring new pharmaceutical solutions to market more quickly. Its focus on AI capabilities positions it as a valuable resource for those looking to innovate and optimize their drug discovery pipelines.